

## 2026 1 Tier Standard - SCHA

### 2026 Step Therapy Criteria

CURRENT AS OF 10/01/2026

## anticonvulsant step therapy

### Products Affected

- *levetiracetam tablet disintegrating soluble 250 mg oral*
- *levetiracetam tablet disintegrating soluble 500 mg oral*
- *perampanel suspension 0.5 mg/ml oral*
- *perampanel tablet 10 mg oral*
- *perampanel tablet 12 mg oral*
- *perampanel tablet 2 mg oral*
- *perampanel tablet 4 mg oral*
- *perampanel tablet 6 mg oral*
- *perampanel tablet 8 mg oral*
- RELGAABI CAPSULE 200 MG ORAL
- RELGAABI CAPSULE 300 MG ORAL
- RELGAABI CAPSULE 400 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 25 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL
- ZONISADE SUSPENSION 100 MG/5ML ORAL

### Details

|          |                                                                                                                                                                                                                                                                                                                                                                                    |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of two generic anticonvulsants. Step 2: Once two generic anticonvulsants have been tried, failed, or contraindicated patients can receive therapy with Spritam, Sympazan, Xcopri, generic perampanel, generic levetiracetam tablet for oral suspension, Relgaabi, or Zonisade oral solution. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## antidepressant step therapy

---

### Products Affected

- EXXUA TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 36.3 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 54.5 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 72.6 MG ORAL
- EXXUA TITRATION PACK TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

### Details

|          |                                                                                                                                                                                                                                                               |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of two generic antidepressants. Step 2: Once two generic antidepressants have been tried, failed, or contraindicated patient can receive therapy with Fetzima or Exxua. |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

# brinzolamide and dorzolamide-timolol PF step therapy

---

## Products Affected

- *brinzolamide suspension 1 % ophthalmic*
- *dorzolamide hcl-timolol mal pf solution 2-0.5 % ophthalmic*

## Details

---

|          |                                                                                                                                                                                                                                                                                                                                                                            |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of formulary dorzolamide or dorzolamide/timolol ophthalmic solution. Step 2: Once dorzolamide or dorzolamide/timolol ophthalmic solution has been tried, failed, or contraindicated the patient can receive therapy with brinzolamide or dorzolamide-timolol PF ophthalmic Solution. |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

---

# drizalma step therapy

---

## Products Affected

- DRIZALMA SPRINKLE CAPSULE  
DELAYED RELEASE SPRINKLE 20  
MG ORAL
- DRIZALMA SPRINKLE CAPSULE  
DELAYED RELEASE SPRINKLE 30  
MG ORAL
- DRIZALMA SPRINKLE CAPSULE  
DELAYED RELEASE SPRINKLE 40  
MG ORAL
- DRIZALMA SPRINKLE CAPSULE  
DELAYED RELEASE SPRINKLE 60  
MG ORAL

## Details

|          |                                                                                                                                                                                                                                                            |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of generic formulary duloxetine. Step 2: Once generic formulary duloxetine has been tried, failed, or contraindicated the patient can receive therapy with drizalma. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

# febuxostat step therapy

---

## Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

## Details

|          |                                                                                                                                                                                                                                       |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of allopurinol tablet. Step 2: Once allopurinol tablet has been tried, failed, or contraindicated patients can receive therapy with Febuxostat. |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

# netarsudil step therapy

---

## Products Affected

- RHOPRESSA SOLUTION 0.02 %  
OPHTHALMIC
- ROCKLATAN SOLUTION 0.02-0.005 %  
OPHTHALMIC

## Details

|          |                                                                                                                                                                                                                                                                 |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of latanoprost or travoprost. Step 2: Once latanoprost or travoprost has been tried, failed, or contraindicated patients can receive therapy with Rhopressa or Rocklatan. |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## ongentys step therapy

---

### Products Affected

- ONGENTYS CAPSULE 25 MG ORAL
- ONGENTYS CAPSULE 50 MG ORAL

### Details

|          |                                                                                                                                                                                                                                                                                       |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, failed, or contraindicated patients can receive therapy with Ongentys. |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

# savella step therapy

---

## Products Affected

- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

## Details

|          |                                                                                                                                                                                                                                                                         |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication to duloxetine, milnacipran or pregabalin. Step 2: Once duloxetine, milnacipran or pregabalin has been tried, failed or contraindicated patients can receive therapy with Savella. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## topical immunomodulators step therapy

---

### Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

### Details

|          |                                                                                                                                                                                                                                                                                                  |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria | Step 1: First line therapy should be a documented trial, failure, or contraindication of two topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, failed, or contraindicated patients can receive therapy with generic pimecrolimus or generic topical tacrolimus. |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## urinary incontinence agents step therapy

---

### Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*

### Details

|                 |                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Criteria</b> | Step 1: First line therapy should be a documented trial, failure or contraindication of 2 of the following: oxybutynin, oxybutynin ER, trospium, tolterodine, tolterodine ER, fesoterodine ER, or solifenacin.<br>Step 2: Once two of the medications listed in Step 1 have been tried, failed, or contraindicated, patients can receive therapy with trospium ER or darifenacin ER |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Index

### B

brinzolamide suspension 1 % ophthalmic... 3

### D

darifenacin hydrobromide er tablet extended  
release 24 hour 15 mg oral..... 10

darifenacin hydrobromide er tablet extended  
release 24 hour 7.5 mg oral..... 10

dorzolamide hcl-timolol mal pf solution 2-  
0.5 % ophthalmic ..... 3

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 20  
MG ORAL ..... 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 30  
MG ORAL ..... 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 40  
MG ORAL ..... 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 60  
MG ORAL ..... 4

### E

EXXUA TABLET EXTENDED RELEASE  
24 HOUR 18.2 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE  
24 HOUR 36.3 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE  
24 HOUR 54.5 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE  
24 HOUR 72.6 MG ORAL..... 2

EXXUA TITRATION PACK TABLET

EXTENDED RELEASE 24 HOUR 18.2  
MG ORAL ..... 2

### F

febuxostat tablet 40 mg oral..... 5

febuxostat tablet 80 mg oral..... 5

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 120 MG ORAL ... 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 20 MG ORAL ..... 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 40 MG ORAL ..... 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 80 MG ORAL ..... 2

FETZIMA TITRATION CAPSULE ER 24

HOUR THERAPY PACK 20 & 40 MG

ORAL..... 2

### L

levetiracetam tablet disintegrating soluble

250 mg oral ..... 1

levetiracetam tablet disintegrating soluble

500 mg oral ..... 1

### O

ONGENTYS CAPSULE 25 MG ORAL.... 7

ONGENTYS CAPSULE 50 MG ORAL.... 7

### P

perampanel suspension 0.5 mg/ml oral..... 1

perampanel tablet 10 mg oral..... 1

perampanel tablet 12 mg oral..... 1

perampanel tablet 2 mg oral..... 1

perampanel tablet 4 mg oral..... 1

perampanel tablet 6 mg oral..... 1

perampanel tablet 8 mg oral..... 1

pimecrolimus cream 1 % external..... 9

### R

RELGAABI CAPSULE 200 MG ORAL ... 1

RELGAABI CAPSULE 300 MG ORAL ... 1

RELGAABI CAPSULE 400 MG ORAL ... 1

RHOPRESSA SOLUTION 0.02 %

OPHTHALMIC ..... 6

ROCKLATAN SOLUTION 0.02-0.005 %

OPHTHALMIC ..... 6

### S

SAVELLA TITRATION PACK 12.5 & 25

& 50 MG ORAL ..... 8

SPRITAM TABLET DISINTEGRATING

SOLUBLE 250 MG ORAL ..... 1

SPRITAM TABLET DISINTEGRATING

SOLUBLE 500 MG ORAL ..... 1

SYMPAZAN FILM 10 MG ORAL..... 1

SYMPAZAN FILM 20 MG ORAL..... 1

SYMPAZAN FILM 5 MG ORAL..... 1

### T

tacrolimus ointment 0.03 % external ..... 9

tacrolimus ointment 0.1 % external ..... 9

tropium chloride er capsule extended

release 24 hour 60 mg oral..... 10

**X**

XCOPRI (250 MG DAILY DOSE)  
TABLET THERAPY PACK 100 & 150  
MG ORAL ..... 1  
XCOPRI (350 MG DAILY DOSE)  
TABLET THERAPY PACK 150 & 200  
MG ORAL ..... 1  
XCOPRI TABLET 100 MG ORAL ..... 1  
XCOPRI TABLET 150 MG ORAL ..... 1  
XCOPRI TABLET 200 MG ORAL ..... 1  
XCOPRI TABLET 25 MG ORAL ..... 1

XCOPRI TABLET 50 MG ORAL ..... 1  
XCOPRI TABLET THERAPY PACK 14 X  
12.5 MG & 14 X 25 MG ORAL..... 1  
XCOPRI TABLET THERAPY PACK 14 X  
150 MG & 14 X200 MG ORAL..... 1  
XCOPRI TABLET THERAPY PACK 14 X  
50 MG & 14 X100 MG ORAL..... 1

**Z**

ZONISADE SUSPENSION 100 MG/5ML  
ORAL..... 1